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ABSTRACT 
 
 
 
 
The World Health Organization (WHO) has defined counterfeit drugs as 
those which are “deliberately mislabelled with respect to identity and/or source”. 
Packaging materials are ubiquitous and manufacturers are able to obtain them from 
multiples of supplier. That is the reason for the unfeasible confiscation. There are a 
few methods used to detect counterfeit products through its packaging: visual 
inspection (visible light) and other optical methods such as infrared and ultraviolet 
analysis as well as pattern recognition. The objective of this study is to differentiate 
the features on the packaging material found from the original and the counterfeit of 
the same fast-moving pharmaceutical products. There are four different product 
packaging investigated obtained through over-the-counter purchase, from the 
complainant or seized by the authority. Firstly, examination is carried out on the 
direct paperboard packaging by comparison; physical examination on the basic 
properties (viz. dimension, thickness and prints), microscopic, optical character 
recognition (OCR) and near infrared analysis. Then, further investigation on the 
information printed and hologram serial number was done. Determination of the 
originality of the products upon procurement was done through authenticating the 
hologram. Microscopic examination on the printed paperboard exhibited consistent 
printing effect for all of the counterfeit and the genuine ones. Results on OCR for 
certain parts of the prints show constant difference between the original and 
counterfeit. However, the IR results indicated that such differences may prove 
inconsistent and hence unreliable to be used for comparison. In conclusion, the 
counterfeit pharmaceutical packaging may be distinguished from the genuine ones 
through physical examination of its basic properties, microscopic observation and 
OCR. 
 
 
 
 
vi 
 
 
 
 
 
ABSTRAK 
 
 
 
 
Pertubuhan Kesihatan Sedunia (WHO) telah mentakrifkan ubat palsu sebagai 
“kesilapan pelabelan yang disengajakan berkenaan dengan identiti dan/atau sumber”. 
Bahan pembungkusan boleh didapati secara meluas daripada sumber pembekal yang 
banyak. Oleh sebab itu, rampasan terhadap bahan mentah pembungkusan untuk 
ubatan palsu sukar dilakukan. Terdapat beberapa kaedah yang biasa digunakan untuk 
mengesan produk palsu melalui pembungkusan: pemeriksaan visual dan kaedah 
optik lain seperti analisis inframerah dan ultralembayung serta pengecaman corak. 
Objektif kajian ini adalah untuk membezakan ciri-ciri bahan pembungkusan yang 
terdapat pada produk tulen dan palsu daripada produk farmaseutikal tertentu. 
Terdapat empat bahan pembungkusan produk yang berbeza diperolehi melalui 
pembelian di kaunter, daripada pengadu atau disita oleh pihak berkuasa. Pemeriksaan 
dijalankan terhadap bungkusan kotak luar dengan membuat perbandingan; 
pemeriksaan fizikal ke atas sifat-sifat asas (dimensi, ketebalan dan cetakan), 
pemeriksaan mikroskopik, pengecaman aksara optik (OCR) dan analisis inframerah. 
Kemudian, siasatan lanjut mengenai maklumat yang tercetak dan nombor siri 
hologram dilakukan. Penentuan awal ketulenan produk dilakukan semasa perolehan 
melalui pengesahan hologram. Pemeriksaan sifat-sifat asas serta mikroskopik ke atas 
kualiti percetakan boleh membezakan antara produk palsu dan tulen. Hasil analisa 
OCR untuk bahagian-bahagian tertentu pada percetakan di luar kotak pembungkusan 
menunjukkan perbezaan antara produk tulen dan palsu. Walau bagaimanapun, 
analisis inframerah menunjukkan spektrum yang tidak dapat membezakan antara 
produk palsu dan produk tulen. Kesimpulannya, bahan pembungkusan produk 
farmaseutikal palsu dan tulen boleh dibezakan menggunakan sifat-sifat asas, 
pemeriksaan mikroskopik dan OCR. 
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CHAPTER 1 
 
 
 
 
INTRODUCTION 
 
 
 
 
1.1 Introduction 
  
 Throughout the chapter, discussion will be from the investigation on the 
information on the paperboard packaging such as the manufacturing date and 
hologram serial number search using the Mediharta Sdn. Bhd. official web site, 
observations using microscope, Fourier transform infrared – attenuated total 
reflectance (FTIR-ATR) and optical character recognition (OCR). The findings of 
the sampling pattern and procurement of the samples will also be discussed.  
 
 
1.2 Research Background  
 
In this study, focussed is on the paperboard packaging. There are several 
analysis to be used on this material. Since the information pertaining to the medicine 
is printed on the paperboard, there is also of importance to analyse this as a way to 
recognize its authenticity. In Malaysia, a medicinal product will only be recognized 
as registered when there are two (2) features; product registration number and 
MeditagTM hologram. Thus, the hologram will also be investigated through its unique 
serial number.  
  
  
 
 
 
2 
 
1.3 Problem Statement 
  
Counterfeit medicine has flooded Malaysia market and has been an issue 
among healthcare professionals. Public seem to have easy access to counterfeit 
medicine rather than the authentic due to the vast availability and cheaper price. 
Usage of counterfeit medicine will endanger lives due to the unknown ingredient in 
the products.  
 
Although the better way to ensure a fake drug is by direct analysis of the 
active pharmaceutical ingredient (API), but this is not feasible due to short course 
therapies and what only remains is the packaging material. Nevertheless, most 
patients/customers will discard the packaging materials as thought to be unimportant 
although it contain most of the information pertaining to the medication.    
 
Furthermore, modus operandi of modern criminals’ separately ship packaging 
materials of the fake and the raw materials for the pharmaceutical dosages makes it 
even harder for the perpetrators to be caught.  
 
Counterfeiting is also a form of intellectual property infringement.  Even 
though this is not of forensic significance but this may be the main reason if a jointly 
effort to be applied in further studies.   
 
The importance to precede such study is to prepare the authorities, stake 
holders and public in differentiating fake medicinal products. For the authorities to 
know that there are such analyses to be done on the packaging and possibly 
determining its source; for the stakeholders to cooperate and challenge the current 
situation on counterfeiting and for the public to be more careful in purchasing their 
health care products to ensure its safety, efficacy and quality.  
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1.4 Research Objectives 
 
The objectives of this study are: 
 
i.  To determine the features on the packaging material found in the original 
and the counterfeit on the same fast-moving pharmaceutical products by 
visual examination. 
ii.  To create a simple, reproducible, reliable and applicable method viz. 
infrared analysis, microscopy observation and pattern recognition for 
early detection of counterfeit in the department. 
 
 
1.5 Scope of the Research 
 
The samples for this study was procured in the state of Johor and only 
accounts for the centre of each districts and regions. Samples consist of three (3) 
Panadol® variant; namely Panadol®, Panadol® Actifast and Panadol® Extend as 
well as one (1) topical antifungal, Creobic® Cream.  
 
Analysis of the packaging material is via visual examination of the printed 
side of the paperboard, microscope observation of the print quality, attenuated total 
reflectance infrared analysis on the paperboard box and the coated surface as well as 
optical character recognition of the printed side of the paperboard.  
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1.6 Significance of Research 
 
 The need to conduct this research is to point out the manifestation of 
counterfeit pharmaceuticals in the market from a scientific point of view. Currently, 
there is no study pertaining to the investigation of these counterfeit from the 
packaging material use in Malaysia. Since there are countless of packaging materials 
suppliers and manufacturers, a better framework must be implemented in the 
packaging material procurement process to reduce the counterfeit products.  
 
There is no provision under the laws enforced by Pharmacy Enforcement 
Division to try cases pertaining to counterfeits. At present, the fake medicinal 
products were prosecuted under different Acts and for offences not mentioning 
counterfeiting; and the practice as stated below: 
 
1. Section 13 Possession for sale of poison and sale of poison, Poisons Act 1952 
which only can try cases where the content has been confirmed containing 
poison as listed in the First Schedule, Poisons List.  
2. Section 15 Adulteration, Sales of Drugs Act 1952 which needs to analyse the 
ingredients and to be compared with the declared content and does not 
provide any means to charge the counterfeiter. 
3. Regulation 29 Directions, Control of Drugs and Cosmetics Regulation 1984 
which states that the Director of Pharmaceutical Services may issue written 
guidelines pertaining to labelling, storage including requirement of the 
containers etc. The labelling includes the use of hologram at point of sale. 
Unfortunately, according to Mediharta Sdn. Bhd., the maker for MeditagTM 
hologram there has not been a case relating to the counterfeit holograms. 
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Recently, Pharmacy Enforcement Johor received information pertaining to 
the supply of packaging material and enquires whether there are any way(s) to 
determine the culprit of this counterfeiting activity. Since the core function of the 
department is to investigate offences made under the act and forensic science may 
contribute to finding the probable source, no doubt this study should be conducted. 
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